MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3760/cma.j.cn112137-20251217-03341

Медицинская библиотека · Zhonghua yi xue za zhi · 2026

[Relationships of PAI-1 gene polymorphisms with the efficacy of ustekinumab in the treatment of patients with Crohn disease].

Xu J Y, Xiong Y J, Lan R T, Chen R, Zhu X Y, Jiang Y

Аннотация на английскомСтатьяПеревод пока не подготовлен

Аннотация

Objective

To explore the relationships of plasminogen activator inhibitor 1 (PAI-1) gene polymorphisms with the efficacy of ustekinumab (UST) in the treatment of patients with Crohn disease (CD).

Methods

The patients with active CD who received UST treatment at the Department of Gastroenterology, the Second Affiliated Hospital of Wenzhou Medical University between January 2021 and January 2025 were retrospectively enrolled. Genotypes of PAI-1 gene at loci rs2227631, rs7242 and rs6092 were examined. The clinical response was evaluated based on the Crohn disease activity index (CDAI) at week 8 of follow-up. All the patients were divided into response group (a decline of CDAI≥100 points compared with week 0 or total CDAI<150 points) and non-response group. According to the CDAI and the simplified endoscopic score for Crohn disease (SES-CD), the deep remission was assessed in the patients who had undergone re-examination of colonoscopy at week 32 of follow-up. These patients were divided into deep remission group (CDAI<150 points, plus SES-CD≤2 points or absence of ulcerations) and non-deep remission group. Those patients who achieved clinical response at week 8 and underwent re-examination of colonoscopy at week 32 were further stratified into deep remission subgroup (CDAI<150 points, plus SES-CD≤2 points or absence of ulcerations) and non-deep remission subgroup. The distribution differences of PAI-1 gene polymorphisms were compared between response group and non-response group, deep remission group and non-deep remission group, as well as deep remission subgroup and non-deep remission subgroup. The genotypes or alleles with distribution differences were included into unconditional logistic regression models to explore the relationships of PAI-1 gene polymorphisms with the efficacy of UST treatment in CD patients.

Results

A total of 191 CD patients were enrolled, 128 males and 63 females, aged (33±12) years. At week 8 of UST treatment, there were 118 patients in response group and 73 patients in non-response group. The homozygous variant genotype (GG) of locus rs2227631 was less frequent in response group than that in non-response group [36.4% (43/118) vs 54.8% (40/73), P=0.039]. The homozygous variant genotype (GG) (OR=0.48, 95%CI: 0.26-0.87) of locus rs2227631 was a factor associated with the clinical response at week 8. At week 32, 176 patients received re-examination of colonoscopy, with 52 patients in deep remission group and 124 patients in non-deep remission group. No significant distribution differences of PAI-1 gene polymorphisms existed between both groups (all P>0.05). Among the 118 patients who achieved clinical response at week 8, 110 patients completed re-examination of colonoscopy, with 39 patients in deep remission subgroup and 71 patients in non-deep remission subgroup. Compared with non-deep remission subgroup, the homozygous variant genotype (GG) [33.3% (13/39) vs 12.7% (9/71), P=0.030] and variant allele (G) [59.0% (46/78) vs 38.7% (55/142), P=0.012] of locus rs7242 were more frequent in deep remission subgroup. The homozygous variant genotype (GG) (OR=2.45, 95%CI: 1.12-5.37) and variant allele (G) (OR=1.88, 95%CI: 1.17-3.03) of locus rs7242 were factors related with the deep remission at week 32 in those patients who achieved clinical response at week 8.

Conclusions

The variation of locus rs2227631 may be associated with a reduced clinical response rate at week 8 in CD patients treated with UST. The variation of locus rs7242 may be related to an increased deep remission rate at week 32 in CD patients who achieved clinical response at week 8. However, the variation of locus rs6092 may not affect the efficacy of UST treatment in CD patients.

Для цитирования: Xu J Y, Xiong Y J, Lan R T, Chen R, Zhu X Y, Jiang Y. [Relationships of PAI-1 gene polymorphisms with the efficacy of ustekinumab in the treatment of patients with Crohn disease].. Zhonghua yi xue za zhi. 2026. DOI: 10.3760/cma.j.cn112137-20251217-03341.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.